Community Health Media

Community Health Media
  • 0.0 (0)
  • Medicine

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts

  1. Aug 13

    This Moment in Medicine: First-Line ADCs in Metastatic TNBC with Dr. Senthil Damodaran

    Are antibody-drug conjugates becoming the new first-line standard for metastatic triple-negative breast cancer? At This Moment in Medicine, hosted by Community Health Media, Dr. Senthil Damodaran reviews the latest data moving ADCs earlier in the treatment landscape for metastatic TNBC. The presentation focuses on TROPION-Breast02, ASCENT-03, and ASCENT-04, comparing datopotamab deruxtecan (Dato-DXd) and sacituzumab govitecan with chemotherapy, with or without pembrolizumab depending on PD-L1 status. Dr. Damodaran also examines efficacy, toxicity, sequencing, and the practical tradeoffs that may influence which ADC clinicians choose. Topics discussed: Historical first-line treatment of metastatic TNBCTROPION-Breast02 and Dato-DXdASCENT-03 and sacituzumab govitecan in PD-L1-negative diseaseASCENT-04 and sacituzumab govitecan plus pembrolizumabProgression-free survival, overall survival, and response ratesToxicity differences between Dato-DXd and sacituzumab govitecanStomatitis, ocular toxicity, neutropenia, and supportive careWhether TROP-2 expression should guide treatmentBRCA mutations and where PARP inhibitors may still fitCNS activity and intracranial diseaseChoosing between Dato-DXd and sacituzumab govitecanADCs sequencing The presentation concludes with a practical discussion on one of the biggest questions in TNBC today: If both ADCs are effective, how should clinicians choose between them? ▶️ Watch more from This Moment in Medicine and subscribe to Community Health Media for expert discussions on the latest advances shaping cancer care. 🎧 Subscribe for the latest insights from leading cancer specialists. #ThisMomentInMedicine #SenthilDamodaran #TripleNegativeBreastCancer #TNBC #ADC #DatoDXd #SacituzumabGovitecan #TROPIONBreast02 #ASCENT03 #ASCENT04 #MedicalOncology #CommunityHealthMedia – Thanks for watching! Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o – Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media

    This Moment in Medicine: First-Line ADCs in Metastatic TNBC with Dr. Senthil Damodaran

  2. Aug 13

    This Moment In Medicine: First-Line HER2+ Metastatic Breast Cancer with Dr. Mothaffar Rimawi

    How should we approach first-line treatment as the HER2-positive metastatic breast cancer landscape rapidly evolves? At This Moment in Medicine, hosted by Community Health Media, Dr. Mothaffar Rimawi examines how new data are reshaping a treatment landscape long defined by the CLEOPATRA regimen. From DESTINY-Breast09 to PATINA and HER2CLIMB-05, Dr. Rimawi explores emerging strategies for deeper HER2 and ER pathway inhibition, the role of T-DXd, and how clinicians might individualize treatment based on disease biology, burden, toxicity, and patient preference. Topics discussed: The evolution of first-line HER2-positive metastatic breast cancer treatmentCLEOPATRA and the foundation of modern HER2-directed therapyPATINA and the addition of palbociclib in HR+/HER2+ diseaseDESTINY-Breast09 and T-DXd plus pertuzumabDepth and duration of response with T-DXdHER2CLIMB-05 and tucatinib maintenanceILD, transaminitis, and other treatment-related toxicitiesPatient-reported outcomes and quality of lifeSelecting treatment based on ER status, CNS disease, disease burden, and molecular profileT-DXd duration and the possibility of induction-maintenance strategiesHow PATINA and HER2CLIMB-05 could inform maintenance therapy The presentation concludes with a panel discussion addressing a critical question for the field: With several highly effective strategies now available, how do we choose the right first-line approach for the right patient? ▶️ Watch more from This Moment in Medicine and subscribe to Community Health Media for expert conversations on the latest advances shaping cancer care. 🎧 Subscribe for the latest insights from leading cancer specialists. #ThisMomentInMedicine #MothaffarRimawi #HER2Positive #MetastaticBreastCancer #DESTINYBreast09 #TDXd #PATINA #HER2CLIMB05 #BreastOncology #MedicalOncology #CommunityHealthMedia – Thanks for watching! Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o – Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media

    This Moment In Medicine: First-Line HER2+ Metastatic Breast Cancer with Dr. Mothaffar Rimawi

  3. Aug 13

    This Moment in Medicine: T-DXd in Early HER2+ BC with Dr. Michelina Cairo

    Where should T-DXd fit in the treatment of high-risk, early-stage HER2-positive breast cancer? At This Moment in Medicine, hosted by Community Health Media, Dr. Michelina Cairo reviews the latest data from DESTINY-Breast11 and DESTINY-Breast05, examining how trastuzumab deruxtecan (T-DXd) could reshape treatment in both the neoadjuvant and adjuvant settings. From pathologic complete response and invasive disease-free survival to ILD risk and treatment sequencing, the presentation explores how clinicians might balance efficacy, toxicity, and individual recurrence risk as T-DXd moves into earlier-stage disease. Topics discussed: Current treatment for high-risk HER2-positive early breast cancerDESTINY-Breast11 and neoadjuvant T-DXd followed by THPPathologic complete response and residual cancer burdenDESTINY-Breast05 and T-DXd versus T-DM1Invasive disease-free survival and emerging CNS outcomesILD, nausea, cardiac safety, and treatment durationNeoadjuvant versus adjuvant use of T-DXdWhether THP alone may be sufficient for selected patientsThe potential role of ctDNAWhere T-DM1 may still fit for residual diseaseIndividualizing treatment according to recurrence risk The presentation concludes with a panel discussion exploring one of the biggest unanswered questions: How much T-DXd is enough—and when should it be used? ▶️ Watch more from This Moment in Medicine and subscribe to Community Health Media for expert conversations on the latest advances shaping cancer care. 🎧 Subscribe for the latest insights from leading cancer specialists. #ThisMomentInMedicine #MichelinaCairo #BreastCancer #HER2Positive #TDXd #TrastuzumabDeruxtecan #DESTINYBreast11 #DESTINYBreast05 #BreastOncology #MedicalOncology #CommunityHealthMedia – Thanks for watching! Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o – Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media

    This Moment in Medicine: T-DXd in Early HER2+ BC with Dr. Michelina Cairo

  4. Aug 13

    This Moment in Medicine: Rethinking Adjuvant Therapy in ER+ Breast Cancer with Dr. Akshjot Puri

    How is adjuvant treatment for ER-positive, HER2-negative breast cancer changing? At This Moment in Medicine, Dr. Akshjot Puri examines key data from OPTIMA, lidERA, NATALEE, and monarchE—and what these trials could mean for chemotherapy de-escalation, endocrine therapy, ovarian suppression, and CDK4/6 inhibitor use. From using Prosigna to identify patients who may be able to avoid chemotherapy to the emerging role of oral SERDs, the presentation highlights how treatment is becoming increasingly individualized based on risk, biology, and patient needs. Topics discussed: OPTIMA and Prosigna-guided chemotherapy de-escalationChemotherapy benefit in premenopausal and postmenopausal patientsThe role of ovarian function suppressionOncotype DX, MammaPrint, and ProsignalidERA and giredestrant in the adjuvant settingNATALEE vs. monarchERibociclib and abemaciclib in early-stage diseasectDNA and emerging biomarkers for treatment selectionIndividualizing therapy for intermediate- and high-risk patients ▶️ Watch more from This Moment in Medicine and subscribe to Community Health Media for expert discussions on the latest advances shaping cancer care. 🎧 Subscribe for the latest insights from leading cancer specialists. #ThisMomentInMedicine #AkshjotPuri #BreastCancer #ERPositive #HER2Negative #OPTIMA #Prosigna #Giredestrant #NATALEE #MonarchE #BreastOncology #CommunityHealthMedia – Thanks for watching! Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o – Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media

    This Moment in Medicine: Rethinking Adjuvant Therapy in ER+ Breast Cancer with Dr. Akshjot Puri

  5. Jul 21

    Drs. Jason Mouabbi, Ruta Rao, & Mark Pegram - Unpacking DESTINY-Breast09 in HER2+ mBC

    A new era in HER2-positive metastatic breast cancer is here.Dr. Jason Mouabbi, Dr. Ruta Rao, and Dr. Mark Pegram break down the groundbreaking DESTINY-Breast09 trial and discuss how trastuzumab deruxtecan (T-DXd) plus pertuzumab is redefining first-line treatment. The conversation explores: Why DB09 may replace the CLEOPATRA standardThe significance of 40+ month median PFSComplete response rates and treatment durabilityManaging ILD, fatigue, nausea, and alopeciaMaintenance therapy strategiesPATINA and HER2CLIMB-05 insightsSequencing after T-DXd progressionWhy “saving your best drug for later” may no longer apply This is a must-watch discussion on the evolving frontline landscape in HER2+ metastatic breast cancer. –Thanks for watching!Our podcasts are also available on: Spotify - https://spotf.fi/chm-podcastAmazon Music - https://amazn.so/chm-podcastApple Podcast - https://podcasts.apple.com/us/podcast...Castbox - https://castbox.fm/vh/6735434Goodpods - https://goodpods.com/profile/chm-111066iHeartRadio - https://iheart.com/podcast/291542082Pocket Casts - https://pca.st/3ncdh11o –Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: Peer to peer interviews, panels & round-tablesCurated live events & conferencesProfessional in-depth content & research updatesInteractive learning modules & webinarsLive & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

    Drs. Jason Mouabbi, Ruta Rao, & Mark Pegram - Unpacking DESTINY-Breast09 in HER2+ mBC

  6. Jul 7

    Dr. Anne O'Dea & Dr. Mabel Mardones - SERENA-6 & ctDNA-Guided Therapy in mBC

    Can we improve outcomes by changing treatment before radiographic progression occurs? In this in-depth discussion, Dr. Anne O'Dea and Dr. Mabel Mardones explore how the SERENA-6 trial is reshaping the management of HR-positive, HER2-negative metastatic breast cancer through ctDNA-guided treatment decisions and earlier intervention for emerging ESR1 mutations. Topics discussed include: The clinical impact of the SERENA-6 trialUsing ctDNA to detect ESR1 mutations before disease progressionWhen and why to switch endocrine therapyCamizestrant and molecularly guided treatment strategiesIntegrating biomarker monitoring into routine clinical practicePatient communication, monitoring, and quality-of-life considerationsPractical challenges and implementation in the community settingFeaturing expert insights from Dr. Anne O'Dea and Dr. Mabel Mardones on one of the most important advances in precision oncology for HR-positive metastatic breast cancer.Watch the full conversation and subscribe for more expert discussions on the latest clinical evidence shaping cancer care. –Thanks for watching!Our podcasts are also available on: Spotify - ⁠https://spotf.fi/chm-podcast⁠Amazon Music - ⁠https://amazn.so/chm-podcast⁠Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠Castbox - ⁠https://castbox.fm/vh/6735434⁠Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠Pocket Casts - ⁠https://pca.st/3ncdh11o⁠ –Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: Peer to peer interviews, panels & round-tablesCurated live events & conferencesProfessional in-depth content & research updatesInteractive learning modules & webinarsLive & on-demand webcasts & podcastsLearn more about us here - ⁠https://communityhealth.media⁠

    Dr. Anne O'Dea & Dr. Mabel Mardones - SERENA-6 & ctDNA-Guided Therapy in mBC

  7. Jun 26

    Dr. Rena Callahan & Dr. Aditya Bardia - Integrating T-DXd in HER2+ Breast Cancer: DB11, DB05 & DB09

    HER2-positive breast cancer treatment is evolving rapidly. With FDA approvals from DESTINY-Breast11 and DESTINY-Breast05, when should clinicians incorporate trastuzumab deruxtecan (T-DXd) into practice—and how should it be used across early-stage and into metastatic disease? In this in-depth discussion, Dr. Rena Callahan and Dr. Aditya Bardia explore how these landmark studies are changing treatment decisions today across neoadjuvant, adjuvant, and metastatic settings—including the management of residual disease and the optimization of first-line metastatic care.Key topics discussed: How DESTINY-Breast11 is changing neoadjuvant treatment strategiesDESTINY-Breast05 and the role of T-DXd for residual diseaseWhich patients should receive T-DXd versus T-DM1Managing ILD risk and monitoring requirementsTreatment decisions for patients who do not achieve pCRRechallenging T-DXd after recurrenceFirst-line metastatic HER2-positive breast cancer after DESTINY-Breast09Deep responses, complete responses, and long-term outcomesT-DXd versus THP in clinical practicePATINA, HER2CLIMB-05, and evolving maintenance strategiesCNS metastases and the role of HER2-targeted ADCsTreatment holidays, ctDNA monitoring, and personalized care As T-DXd moves into earlier lines of therapy, oncologists are facing new questions around sequencing, toxicity management, and optimizing long-term outcomes. This conversation provides practical insights for both academic and community clinicians navigating this rapidly changing landscape. Subscribe for more expert oncology discussions, breast cancer updates, and clinical trial insights from Community Health Media. –Thanks for watching!Our podcasts are also available on: Spotify - ⁠https://spotf.fi/chm-podcast⁠Amazon Music - ⁠https://amazn.so/chm-podcast⁠Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠Castbox - ⁠https://castbox.fm/vh/6735434⁠Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠Pocket Casts - ⁠https://pca.st/3ncdh11o⁠ –Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: Peer to peer interviews, panels & round-tablesCurated live events & conferencesProfessional in-depth content & research updatesInteractive learning modules & webinarsLive & on-demand webcasts & podcastsLearn more about us here - ⁠https://communityhealth.media⁠

    Dr. Rena Callahan & Dr. Aditya Bardia - Integrating T-DXd in HER2+ Breast Cancer: DB11, DB05 & DB09

  8. Jun 26

    Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, & Dr. Ana Garrido-Castro - Evolving ADCs in 1L mTNBC

    The first-line treatment landscape for metastatic triple-negative breast cancer is changing rapidly. Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, and Dr. Ana Garrido-Castro discuss how ADCs are reshaping frontline TNBC care and what the latest clinical evidence means for real-world practice. The conversation explores: The evolution of metastatic TNBC treatmentWhy many patients never reach second-line therapyThe impact of ASCENT and sacituzumab govitecanASCENT-03 and ASCENT-04 trial resultsTROPION-Breast02 and datopotamab deruxtecanThe role of crossover in interpreting overall survivalPFS, OS, and PFS2 as clinical trial endpointsSelecting between SG and Dato-DXdManaging neutropenia, stomatitis, ocular toxicity, and ILDShared decision-making in frontline TNBCWhy using the best therapy first may matter mostThis comprehensive discussion examines the evidence driving ADC use in metastatic TNBC and how clinicians can individualize treatment selection in an increasingly complex therapeutic landscape. Watch now to hear how ADCs are reshaping frontline TNBC care. –Thanks for watching!Our podcasts are also available on: Spotify - ⁠https://spotf.fi/chm-podcast⁠Amazon Music - ⁠https://amazn.so/chm-podcast⁠Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠Castbox - ⁠https://castbox.fm/vh/6735434⁠Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠Pocket Casts - ⁠https://pca.st/3ncdh11o⁠ –Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: Peer to peer interviews, panels & round-tablesCurated live events & conferencesProfessional in-depth content & research updatesInteractive learning modules & webinarsLive & on-demand webcasts & podcastsLearn more about us here - ⁠https://communityhealth.media⁠

    Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, & Dr. Ana Garrido-Castro - Evolving ADCs in 1L mTNBC
See All (70)

About

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts

Information

  • Creator
    Community Health Media
  • Years Active
    2025 - 2026
  • Episodes
    70
  • Rating
    Clean
  • Copyright
    © Community Health Media
  • Show Website
    Community Health Media

You Might Also Like